Cochlear (ASX: COH) shares rebound as FY27 guidance tests recovery after historic sell-off

Cochlear Limited (ASX: COH) has ended FY26 at the upper end of its dramatically reduced earnings guidance, with second-half sales growth accelerating to 6% in constant currency and FY27 underlying profit guidance coming in ahead of recent market expectations. The hearing-implant company generated A$2.343 billion of sales and A$322.4 million of underlying net profit, but those numbers remain 22% below the previous year’s underlying earnings as flat cochlear implant revenue, a three-percentage-point gross-margin decline and foreign-exchange pressure weighed heavily on profitability. Investors nevertheless pushed Cochlear shares around 6.2% higher to approximately A$139.36 during August 18 morning trade, suggesting the market is beginning to focus on whether April’s historic earnings downgrade marked the low point rather than the start of a prolonged deterioration. The central FY27 question is now whether modest implant-market recovery, stronger referral pathways and lower fixed costs can rebuild profit even though management expects gross margin to remain around the depressed FY26 level.

The FY26 result still documents a severe reset. Reported sales declined 1% to A$2.343 billion, underlying net profit fell 22% to A$322.4 million and statutory profit collapsed 62% to A$147.3 million. Gross margin fell from 74% to 71%, while underlying EBIT dropped 22% to A$432.6 million and the underlying net profit margin contracted from 18% to 14%. Cochlear also cut its final dividend 40% to A$1.30 per share, taking the full-year dividend down 20% to A$3.45.

The significance of August 18 is therefore not that Cochlear has returned to its previous earnings trajectory. It has not. The significance is that the company finished FY26 at the top end of the A$290 million to A$330 million profit range established after April’s downgrade and has now guided to A$330 million to A$350 million of underlying profit for FY27. At the A$340 million midpoint, that would represent only about 5.5% growth from FY26, but Market Index noted that both the FY26 result and FY27 guidance were above Macquarie estimates.

Why did Cochlear shares rise when underlying profit still fell 22% in FY26?

The market is comparing today’s result with expectations formed after April rather than with the much stronger FY25 earnings base. Cochlear had entered FY26 expecting underlying net profit of A$435 million to A$460 million before cutting that range to A$290 million to A$330 million on April 22 as developed-market demand weakened, Middle East disruption intensified and the stronger Australian dollar reduced earnings. The downgrade triggered a 40.7% one-day share-price collapse, the worst session in Cochlear’s listed history.

Against that reset expectation, A$322.4 million of FY26 underlying profit represented a better finish than some investors had feared. Constant-currency second-half revenue growth of 6% was also materially stronger than the first-half performance, when constant-currency revenue had declined 2%. That sequential improvement does not erase the annual earnings decline, but it provides evidence that demand and product momentum were improving late in the year.

The share-price context is equally important. At approximately A$139.36 during late-morning August 18 trading, Cochlear was around 7% above its August 11 close and roughly 17% above its July 17 close. Yet the stock remained approximately 55% below the A$311.99 52-week high and about 57% above the A$88.74 annual low. The recovery is therefore meaningful but still represents only a partial reversal of one of the largest valuation collapses seen among major ASX healthcare companies in recent years.

That gap explains why a relatively modest FY27 recovery can support a positive market response. Investors are no longer asking Cochlear to immediately return to the A$435 million-plus profit once expected for FY26. They are first looking for evidence that earnings have stabilised and that the April downgrade did not expose a structural loss of competitive position.

Why did cochlear implant units rise 5% while implant revenue failed to grow?

Cochlear sold 56,692 cochlear implants in FY26, up 5% from 53,968, yet cochlear implant revenue was flat in constant currency at approximately A$1.435 billion. The difference was driven primarily by a greater mix of lower-priced emerging-market units. Implants still represented about 61% of group revenue, making this disconnect between volume and revenue one of the most important issues in the result.

Developed-market revenue increased only 1% in constant currency. United States revenue rose 4%, supported by stronger performance where Cochlear had greater visibility over patient referral pathways, while Western Europe declined 8% amid elective-surgery backlogs in the United Kingdom, industrial action in Spain and lower market share in Germany. Asia Pacific performed better, with revenue increasing 7% and Australian private-hospital growth benefiting from referral initiatives.

Emerging markets moved in the opposite direction. Revenue declined 2% in constant currency as strength in Latin America and Eastern Europe was outweighed by weaker Middle East and China performance. Middle East access was disrupted by regional conflict, while China volumes were offset by lower average selling prices following volume-based procurement and reimbursement reductions.

This is why unit growth alone cannot establish that the implant franchise has returned to strong commercial growth. If incremental units are concentrated in lower-priced markets while developed-market surgery volumes remain soft, revenue can lag procedure growth and margins can remain under pressure. Cochlear’s FY27 guidance explicitly assumes only modest implant revenue growth in both developed and emerging markets, rather than a rapid return to historical growth rates.

Can the Nucleus Nexa System rebuild developed-market growth after its difficult first year?

The Nucleus Nexa System has already achieved extremely high adoption within Cochlear’s own developed-market sales mix. By June, Nexa represented more than 95% of implant sales across developed markets, compared with more than 80% by the end of the first half. Cochlear also achieved an average price increase of approximately 3% alongside the rollout.

That adoption rate removes one potential concern. The FY26 weakness was not caused primarily by clinicians refusing to transition to Nexa once the product was available. Instead, broader market growth was softer than expected and the contracting process took longer than management had initially assumed, while country-specific healthcare-system bottlenecks constrained procedures.

The harder question is whether Nexa can generate incremental demand rather than simply replace older Cochlear implant systems. Management views the platform as the foundation for future products including a drug-eluting electrode and a totally implantable cochlear implant. The system’s upgradeable architecture is also intended to support future diagnostic and personalised-care capabilities.

Those longer-term opportunities explain why research and development spending increased 15% to A$323.2 million, equivalent to around 14% of FY26 sales. Cochlear expects R&D spending to remain around 13% of sales in FY27 despite its current margin pressures.

That is an aggressive but understandable capital-allocation choice. Cutting R&D deeply could improve short-term earnings while weakening the product pipeline that supports Cochlear’s competitive position over the next decade. The company is instead attempting to reduce support and fixed costs while protecting growth investment.

Why has Cochlear’s gross margin fallen from 74% to 71%, and can it recover?

The gross-margin decline is arguably the clearest explanation for the FY26 earnings contraction. Cochlear said sales mix reduced gross margin by approximately 1.5 percentage points, manufacturing variances reduced it by another 1.2 percentage points and foreign exchange took approximately 0.6 percentage points. Those effects pushed gross margin from 74% to 71%.

Manufacturing utilisation is particularly important. Cochlear reduced production after demand came in below expectations, which meant fixed manufacturing overheads were spread across fewer units. This is a classic operating-leverage problem: when production volumes fall below planned levels, unit economics deteriorate even if the company has not suffered an equivalent increase in absolute manufacturing costs.

FY27 guidance suggests investors should not expect an immediate margin rebound. Cochlear expects gross margin of approximately 70% to 71%, broadly similar to FY26. Lower China pricing and foreign-exchange effects are expected to offset improvements in cost of goods sold and manufacturing overhead recovery, although the Chengdu manufacturing facility is expected to reach break-even during FY27.

This makes the FY27 profit guidance more interesting. If Cochlear can increase underlying profit from A$322.4 million toward the A$340 million midpoint while gross margin remains broadly flat, the improvement must come predominantly from revenue growth, cost discipline and better operating leverage below gross profit rather than a simple rebound in product margins.

That also explains management’s medium-term focus. Cochlear continues to target an 18% net profit margin compared with only 14% in FY26, but it has not suggested that this four-percentage-point gap will close in FY27.

Can medical referral programs solve Cochlear’s adult implant growth problem?

Cochlear increasingly believes that the bottleneck in developed markets is not simply awareness among potential recipients but an inconsistent pathway from hearing-loss diagnosis to specialist referral and eventual surgery. Management says medical and professional referrals generally convert at higher rates, yet they currently account for only around 40% of adult cochlear implant referrals in the United States.

The company is therefore spending more heavily on what it calls the medicalisation of hearing loss. Referral capabilities have been developed in the United States, Germany, the United Kingdom and Australia, while referral propensity is being tracked across nearly 10,000 accounts and more than 1,500 referrer contacts in the United Kingdom, Germany and Australia.

Early results provide some evidence that the approach can work. Cochlear said improved referrals contributed to more than 15% growth in Australian private hospitals during FY26, while quality referrals in the United Kingdom have nearly doubled over four years. Education and referral pilots operating in four major United States cities are planned to expand to 12.

Management has freed approximately A$25 million of additional FY27 growth investment through fixed-cost reductions to support initiatives including referral programs, digital candidate tools, clinician workflow improvements and evidence generation for payers and policymakers. That A$25 million is equivalent to nearly 8% of FY26 underlying net profit, making the program financially material rather than a minor marketing experiment.

The commercial logic is compelling if conversion improves. Cochlear does not need to manufacture an entirely new category of demand if large numbers of potentially eligible adults already exist but fail to progress through the healthcare system. The risk is timing. Management itself cautions that many of these initiatives will take time to translate into more consistent growth, which is why FY27 guidance assumes only modest developed-market implant revenue improvement.

Why are Services becoming more important as new implant revenue struggles?

Services generated A$634.9 million of FY26 sales, approximately 27% of group revenue, and increased 6% in constant currency. Developed-market Services revenue grew 13%, supported by a larger eligible recipient base, stronger Nucleus 8 Sound Processor demand and improved reimbursement workflows.

This installed-base revenue provides an important counterweight when new implant procedures soften. Every additional recipient potentially becomes a long-duration customer for replacement sound processors, accessories and related services, meaning historical implant growth can continue generating revenue years after the original procedure.

The current processor replacement cycle is, however, beginning to mature. Cochlear expects Services growth to slow in FY27 and to be weighted toward the first half. Investors therefore cannot assume that Services will continue expanding at the same rate indefinitely while implant revenue remains flat.

Acoustics is smaller, generating A$273.3 million or roughly 12% of FY26 sales. Constant-currency revenue increased only 1%, although second-half growth improved to 5% as the Osia System expanded into Western Europe and Asia Pacific. FY27 growth is expected to benefit from the Osia 3 Sound Processor following regulatory approvals.

The revenue mix therefore gives Cochlear some resilience, but the core implant business still needs to resume growth. Services can soften earnings volatility, but a company valued historically as a premium global medical-device growth business ultimately needs rising procedure numbers and implant revenue.

Does A$264 million of free cash flow make Cochlear’s earnings decline less concerning?

Cash flow was considerably stronger than the profit trend. Operating cash flow increased A$130.4 million to A$368 million and free cash flow more than doubled from A$122.4 million to A$263.5 million. The improvement was driven primarily by working-capital normalisation following inventory and receivables investment ahead of the Nexa launch.

Net cash nevertheless declined by A$88 million to A$187.7 million after dividends, cloud investment, capital expenditure and other cash movements. Cochlear kept its on-market share buyback inactive because net cash remained slightly below its approximately A$200 million target.

Cloud investment remains another temporary drag. Cochlear recorded A$66 million of after-tax cloud-related expense in FY26 and expects another approximately A$60 million after tax in FY27 before the program is completed. The company treats those costs as significant items outside underlying profit, but they remain genuine cash expenditure.

The stronger free cash flow therefore improves financial flexibility without removing the need for disciplined capital allocation. Cochlear is simultaneously funding R&D, referral initiatives, cloud modernisation and A$100 million to A$110 million of expected FY27 capital expenditure while maintaining a dividend policy targeting 70% of underlying profit.

Why is foreign exchange still a major threat to Cochlear’s FY27 profit recovery?

Foreign exchange reduced FY26 underlying profit by approximately A$24 million relative to the spot rates incorporated into the original August 2025 guidance. The stronger Australian dollar is expected to remain a significant issue in FY27 because much of Cochlear’s revenue is earned internationally while a meaningful portion of its cost base remains Australian-dollar denominated.

FY27 guidance assumes an Australian dollar of US$0.70 and €0.61, compared with FY26 average rates of US$0.68 and €0.58. At those assumptions, Cochlear estimates that currency translation would reduce underlying profit by approximately 10% relative to FY26 average exchange rates before partial offsets from hedging gains.

That makes the A$330 million to A$350 million profit guidance more demanding than the headline growth rate initially appears. Cochlear is guiding to approximately 2.4% to 8.6% underlying profit growth despite expecting material foreign-exchange pressure and little gross-margin recovery.

If currency moves more favourably, earnings could receive some assistance. If the Australian dollar strengthens further than management’s assumptions, the hurdle rises. Either way, currency remains an important variable outside management’s direct operational control.

Key takeaways from Cochlear’s FY26 results and FY27 recovery outlook

• Cochlear reported FY26 sales of A$2.343 billion, up 2% in constant currency but down 1% on a reported basis.
• Underlying net profit fell 22% to A$322.4 million, while statutory profit declined 62% to A$147.3 million.
• Second-half constant-currency revenue growth accelerated to 6%, helping Cochlear finish at the upper end of its reduced FY26 earnings guidance.
• Cochlear implant volumes increased 5% to 56,692, but implant revenue remained flat in constant currency because of a greater mix of lower-priced emerging-market sales.
• Gross margin fell from 74% to 71% and is expected to remain around 70% to 71% in FY27 rather than immediately recovering.
• The Nucleus Nexa System represented more than 95% of developed-market implant sales by June and achieved an average price increase of approximately 3%.
• Services revenue increased 6% in constant currency to A$635 million, providing a growing recurring-style revenue stream from Cochlear’s installed recipient base.
• Cochlear expects FY27 underlying net profit of A$330 million to A$350 million, with the A$340 million midpoint approximately 5.5% above FY26.
• Free cash flow increased to A$263.5 million, although net cash fell to A$187.7 million and the share buyback remained inactive.
• Cochlear shares were around A$139.36 during August 18 morning trade, up about 6.2% for the session but still more than 55% below their 52-week high.

What will prove whether Cochlear’s post-crash recovery has genuinely started?

Cochlear’s FY26 result is not a return to normal. Underlying profit remains A$92 million below FY25, implant revenue did not grow, gross margin is three percentage points lower and the final dividend has been cut 40%. The business that entered FY26 targeting more than A$435 million of profit finished with A$322.4 million, so the damage behind April’s historic share-price collapse was real rather than simply a temporary market overreaction.

What August 18 provides is evidence that the deterioration may have stopped accelerating. Second-half sales improved, Nexa adoption reached more than 95% of developed-market implant sales, free cash flow strengthened and FY27 profit guidance came in above the Macquarie estimate cited by Market Index. The share-price rebound reflects that more constructive starting point rather than an assumption that the previous earnings trajectory has already returned.

The most important FY27 proof point will be developed-market implant revenue. If referral programs translate into more surgeries in the United States, Europe and Australia while Nexa maintains pricing and market share, Cochlear could begin rebuilding operating leverage even with gross margin around 70% to 71%. Services and Acoustics can support the recovery, but they cannot indefinitely compensate for stagnant revenue in the company’s largest product category.

A second test will be margin progression below gross profit. Management has already reduced fixed costs to fund another A$25 million of growth investment while expecting reported operating expenditure to decline slightly. If underlying profit reaches the A$340 million midpoint despite foreign-exchange pressure and flat gross margins, that would provide tangible evidence that the cost reset is creating leverage.

The weaker scenario is that implant-market growth remains inconsistent, China pricing falls further, Middle East disruption persists and the stronger Australian dollar absorbs the benefits of cost reduction. That could leave Cochlear trapped around a lower earnings base even while its long-term technology pipeline remains attractive.

The April crash removed much of the valuation premium that had accumulated around Cochlear’s historical growth record. August 18 shows investors are prepared to rebuild some of that confidence, but the next rerating will require more than landing at the top of downgraded guidance. Cochlear now has to prove that A$322.4 million was the bottom of the earnings cycle and not the new normal.